5-MeO-DMT Vaporizable Compositions for PTSD Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved compositions for the vaporization of 5-MeO-DMT that enhance treatment efficacy for psychological disorders, particularly trauma-related or stressor-related disorders, by optimizing vaporization efficiency and viscosity control.
Innovation Solution
The development of compositions comprising 5-MeO-DMT in combination with one or more diluents, such as triethyl citrate, propylene glycol, vegetable glycerin, polyethylene glycol, terpenoids, and cannabinoid distillates, which achieve a viscosity range of 400 cP to 150,000 cP, thereby improving vaporization efficiency and reducing leaking, clogging, and thermal degradation in vape systems.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If 5-MeO-DMT is vaporized directly without diluents, then the substance can be vaporized, but the viscosity control is poor and vaporization efficiency is reduced
Solution Approach 1:
The patent introduces diluents (vegetable glycerin, propylene glycol, terpenoids, or cannabinoid distillates) as intermediary substances to mix with 5-MeO-DMT. These diluents act as mediators that improve the flow properties and vaporization characteristics of the composition without interfering with the therapeutic effect of 5-MeO-DMT, thereby resolving the contradiction between vaporization efficiency and viscosity control
Solution Approach 2:
The patent optimizes the ratio of 5-MeO-DMT to diluent to achieve specific viscosity ranges (400-150,000 cP). By adjusting this compositional parameter, the invention transforms the physical properties of the mixture to enable efficient vaporization while maintaining controllable viscosity, thus resolving the technical contradiction
2Productivity
If heating temperature is increased to improve vaporization efficiency, then vaporization efficiency improves, but thermal degradation and combustion occur
Solution Approach 1:
The diluents in the composition modify the thermal properties of the mixture, allowing vaporization to occur at lower temperatures that prevent combustion and thermal degradation of 5-MeO-DMT while still achieving efficient vaporization. The presence of these diluents changes the heating parameters needed for effective vaporization
Solution Approach 2:
The diluents serve as thermal buffers that protect 5-MeO-DMT from excessive heat exposure. They absorb and distribute heat more evenly, preventing localized overheating and combustion while maintaining sufficient vaporization efficiency
3Reliability
If 5-MeO-DMT concentration is increased in the composition, then treatment efficacy improves, but viscosity control becomes difficult and vaporization efficiency decreases
Solution Approach 1:
The patent establishes optimal concentration ranges and ratios of 5-MeO-DMT to diluents that balance treatment efficacy with vaporization performance. By controlling these compositional parameters, the invention maintains high 5-MeO-DMT content for therapeutic effect while ensuring the mixture remains vaporizable with acceptable efficiency
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compositions provide improved vaporization efficiency, leading to more consistent dosing and reduced thermal degradation byproducts, effectively treating psychological disorders when administered via inhalation of the vaporized composition.
Implementation Method 1
Vaporization involves heating the substance to a temperature that is high enough to convert its active compounds into gaseous vapor
Data Source
AI summary
The present application describes compositions comprising 5-MeO-DMT, one or more diluents, and optionally a cannabinoid compound for inhalation through vaporization. In certain embodiments, the compositions can be utilized as a treatment of trauma-related disorder or stressor-related disorder, such as post-traumatic stress disorder (PTSD), acute stress disorder (ASD), reactive attachment disorder (RAD), and disinhibited social engagement disorder (DSED). In particular embodiments, the composition comprises about 15-45% 5-MeO-DMT and 15-35% CBD dissolved in triethyl citrate or alpha-bisabolol, which has been observed herein to effectively remedy patients' anxiety and stress.